Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67837 | 0.94 | PKM (0.67) | PKMALDH1A1PTGS2MMP2CA1 | |
| SCHEMBL6108870 | 0.94 | PKM (0.67) | PKMALDH1A1PTGS2MMP2CA1 | |
| SCHEMBL924893 | 0.88 | PKM (0.59) | PKMALDH1A1PTGS2MMP2CA1 | |
| Methylene Chloride SCHEMBL28109382 | 0.88 | PKM (0.59) | PKMALDH1A1PTGS2MMP2CA1 | |
| SCHEMBL788413 | 0.82 | ABL1 (0.54) | PKMALDH1A1PLAU | |
| SCHEMBL2325334 | 0.82 | PLAU (0.57) | CA1CA2PLAUCA9 | |
| SCHEMBL150162 | 0.82 | ALDH1A1 (0.60) | PKMALDH1A1CA1CA2HSD17B10 | |
| SCHEMBL5891023 | 0.82 | ALDH1A1 (0.60) | PKMALDH1A1CA1CA2HSD17B10 | |
| SCHEMBL7503391 | 0.81 | PTGS2 (0.71) | PKMKDM4EALDH1A1PTGS2PTGS1 | |
| SCHEMBL7076663 | 0.80 | F2 (0.56) | PKMKDM4EALDH1A1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125226-B2 | Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2018-11-13 | — | — | US | claimed |
| US-20140364566-A1 | SCALE-UP PROCESS OF BIFUNCTIONALIZED TRIBLOCK COPOLYMERS WITH SECONDARY AND TERTIARY AMINES, WITH APPLICATION IN DEWATERING AND DESALTING OF HEAVY CRUDE OILS | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2014-12-11 | — | — | US | claimed |
| WO-2025236011-A1 | COMPOSITIONS FOR PHOSPHOROUS-AZOLE EXCHANGE CHEMISTRY AND USE THEREOF TO TARGET FUNCTIONAL PROTEIN SITES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4377295-B1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-06-11 | — | — | EP | disclosed |
| US-20240217928-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240217928-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4377295-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2023006645-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006645-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-02-02 | — | — | WO | disclosed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| US-20010056184-A1 | Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| WO-2001070690-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070682-A2 | CARBOCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070691-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070720-A2 | CARBOCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001027084-A1 | BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0939629-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998003166-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | PKM 2642/4885KDM4E 2097/4885ALDH1A1 1394/4885 |
| US-20010056184-A1 | Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds | NCEH1, NOP10, HRH1 | PKM 4753/4885KDM4E 2189/4885ALDH1A1 4061/4885 |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | PKM 890/4885KDM4E 1361/4885ALDH1A1 3985/4885 |
| US-20240217928-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | NHERF1, ENPP1, ATP6AP1 | PKM 3492/4885KDM4E 4376/4885ALDH1A1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.